trial · primary record
BupiZenge 25 mg
Head & Neck Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 150 |
| Primary completion | 2027-01-31 |
| Primary endpoint | Total pain reduction in oral cavity pain over 3 hours after taking study treatment on the last day of radiotherapy |
| Registry ID | NCT07672236 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:21.625Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07672236
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.